# Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE

> **NCT04643067** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kangpu Biopharmaceuticals, Ltd.** · enrollment: 64 (actual)

## Conditions studied

- SLE; Drug

## Interventions

- **DRUG:** KPG-818 low dose
- **DRUG:** KPG-818 mid dose
- **DRUG:** KPG-818 high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04643067
- **Lead sponsor:** Kangpu Biopharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-03
- **Primary completion:** 2023-08-18
- **Final completion:** 2023-08-18
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04643067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04643067, "Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04643067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*